Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03406572
Other study ID # K160911J
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 18, 2018
Est. completion date August 18, 2023

Study information

Verified date September 2023
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic respiratory insufficiency and COPD are the third leading cause of death worldwide. Patients decompensate at various stages of their disease and exhibit acute-on-chronic respiratory failure (ACRF), a frequent cause of ICU hospitalization for hypercapnic acute respiratory failure (ARF). Non-invasive ventilation (NIV) is the first line ventilatory treatment for hypercapnic ARF. It is applied intermittently, separated by periods of spontaneous breathing (SB) with standard oxygen (O2). Standard O2 has drawbacks that limit the benefit of intermittent NIV in hypercapnic ARF: limited gas flow which is well below the patient's inspiratory flow rate, limited capacity and efficiency of oxygenation with non-controlled FiO2 (risk of excessive oxygen and induced hypercapnia), and cold and dry gas leading to discomfort and under-humidification of the airways and tracheobronchial secretions. Benefits in terms of work of breathing and CO2 removal resulting from PEEP and pressure support applied during NIV periods could be rapidly lost during standard O2. Recently, use of high-flow heated and humidified nasal oxygen therapy (HFHO) has gained enthusiasm among intensivists to manage ARF. HFHO delivers high flows (up to 60L/min, that generate moderate PEEP) of heated and humidified oxygen at a controlled and adjustable FiO2 (21 to 100%) that rapidly improve respiratory distress symptoms, oxygenation, respiratory comfort and outcome of patients with hypoxemic ARF. These unique features of HFHO could overcome some of the drawbacks of standard O2 during SB periods in hypercapnic ARF. Indeed, PEEP effect, washout of nasopharyngeal dead-space limiting CO2 re-breathing and inspired gas conditioning preserving adequate mucosal function and secretion removal, could potentially contribute to decrease airways resistance, intrinsic PEEP and work of breathing, while improving patient comfort. Investigators aim to determine if the use of HFHO, as compared to standard O2, increases the number of ventilator-free days (VFDs) and alive at day 28 in patients with hypercapnic ARF admitted in an ICU, an intermediate care, or a respiratory care unit, and requiring NIV.


Description:

In both groups, treatment will start with a first NIV session of 2 hours, with arterial blood gas measurement between one hour and two hours after initiating the NIV session. The NIV will be extended for those patients with a pH < 7.30. In both groups, patients will be assessed for their tolerance of NIV and their ability to switch to spontaneous breathing every hour +/- 30 min, except during sleep (10 pm-8 am); they will be assessed for their tolerance of spontaneous breathing and for the need of resumption of NIV every 2 hours+/- 30 min and every 4 +/- 1 hours thereafter. To ensure the consistency of indications of NIV and invasive mechanical ventilation (IMV) across centers and reduce potential bias, NIV and IMV will be initiated and stopped in the same way in the two groups, using predefined criteria. - Inclusion (day 0): informed consent, randomisation (HFHO group/standard O2 group), NIV initiation (for 2 hours), clinical and paraclinical exam including ABG, data collection - Follow-up (day 1 to day 28) : NIV, clinical exam, ABG, data collection


Recruitment information / eligibility

Status Completed
Enrollment 161
Est. completion date August 18, 2023
Est. primary completion date June 18, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria - Adult patients aged 18 or above, admitted to an ICU, an intermediate care or a respiratory care unit; - Chronic respiratory disease previously documented or strongly suspected on clinical, radiological and blood gazes data and pulmonary function tests, in connection with an obstructive respiratory disease (COPD, emphysema, overlap-syndrome (COPD + obstructive sleep apnoea) or mixed (bronchiectasis, obesity-hypoventilation syndrome)) - Patients requiring NIV for hypercapnic ARF (whatever the precipitating cause) i.e. with clinical signs of moderate to severe respiratory distress : dyspnea and /or respiratory rate > 25/min and/or use of accessory respiratory muscles and/or paradoxical abdominal motion and/or signs of respiratory encephalopathy (sleepiness, asterixis, confusion); and respiratory acidosis on arterial blood gases, defined by pH<7.35 and PaCO2 > 45 mmHg despite the careful supply of oxygen and appropriate therapy that may include bronchodilators, corticosteroids and antibiotics Exclusion criteria - Contraindications to NIV; - Purely restrictive lung disease (thoracic deformity, neuro-muscular pathology) and pure obstructive sleep apnoea (without spirometric disturbance or daytime gas anomaly) - Immediate need for intubation (respiratory or cardiac arrest); - Persistent hemodynamic instability (use of vasopressors for > 1 hour); - Multiple organ failure (score SOFA>6); - NIV treatement for >3 consecutive hours (without any interruption) before admission to ICU, intermediate care, or respiratory care unit and before randomization; - Anticipated difficulties to conduct NIV (facial trauma or deformation, edentulous patient); - End stage chronic respiratory insufficiency (defined as use of NIV at home or CPAP treatment at home and life expectancy below 6 month); - Non-treated pneumothorax; - Impossibility to perform subjective assessment of dyspnea and comfort (cognitive impairment); - Patient under guardianship or trusteeship; - Pregnancy/breastfeeding; - Decision to withhold or to withdraw life-sustaining treatments (including intubation) - Moribund state - Current participation in another clinical trial with an endpoint related to NIV. - No affiliation to social security (beneficial or assignee); - Refusal to participate to the study (patient or legal representative or family member or close relative if present

Study Design


Intervention

Device:
HFHO Group
Common name: humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases Brand name: Airvo 2
Standard O2
Standard oxygen therapy

Locations

Country Name City State
France Service de Réanimation Médico-Chirurgicale, Hôpital Louis Mourier Colombes

Sponsors (2)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris Direction Générale de l'Offre de Soins

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of ventilator-free days (VFDs) alive At day 28 after study enrollment
Secondary Delay of completion of stopping rules for NIV 28 days post-randomisation
Secondary Patient self-assessement of comfort during each SB period measured by Visual Analog Scale (score range 0-10, higher values represent a better outcome) After 2 hours of SB in the 48 first hours, and every 4 hours thereafter, up to 28 days
Secondary Nurse assessement of comfort during each SB period measured by Likert scale (score range1-5; higher values represent a better outcome) After 2 hours of SB in the 48 first hours, and every 4 hours thereafter, up to 28 days
Secondary Hospital length of stay 28 days post-randomisation
Secondary All cause mortality 28 days post-randomisation
Secondary Proportion of patients with facial skin erythema and/or ulceration After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days
Secondary Number of NIV sessions 28 days post-randomisation
Secondary Duration of NIV sessions (hours) 28 days post-randomisation
Secondary Number of days between the day the patient first meets criteria for NIV cessation and day 28 post-randomization 28 days post-randomisation
Secondary Number of days between the day of initially achieving unassisted ventilation and day 28 post-randomization (i.e. after having successfully spent 48 consecutive hours of unassisted breathing) 28 days post-randomisation
Secondary Proportion of patients achieving 48 consecutive hours of daytime unassisted breathing 28 days post-randomisation
Secondary Proportion of patients requiring NIV resumption after 48 consecutive hours of daytime unassisted breathing 28 days post-randomisation
Secondary Patient self-assessement of comfort during each NIV period measured by Visual Analog Scale (score range 0-10, higher values represent a better outcome) after 1 hour of NIV, up to 28 days
Secondary Nurse assessement of comfort during each NIV period measured by Likert scale (score range1-5; higher values represent a better outcome) after 1 hour of NIV, up to 28 days
Secondary Patient self-assessement of dyspnea during each SB period measured by Visual Analog Scale (range 0-10; higher values represent a worst outcome) after 2 hours of SB in the 48 first hours, and every 4 hours thereafter, up to 28 days
Secondary Nurse assessement of dyspnea during each SB period measured by Likert scale (score range1-5; higher values represent a worst outcome) after 2 hours of SB in the 48 first hours, and every 4 hours thereafter, up to 28 days
Secondary Patient self-assessement of dyspnea during each NIV period measured by Visual Analog Scale (range 0-10; higher values represent a worst outcome) after 1 hour of NIV, up to 28 days
Secondary Nurse assessement of dyspnea during each NIV period measured by Likert scale (score range1-5; higher values represent a worst outcome) after 1 hour of NIV, up to 28 days
Secondary Respiratory rate during SB periods after 2 hours of SB in the 48 first hours, and every 4 hours thereafter, up to 28 days
Secondary Respiratory rate during NIV periods after 1 hour of NIV, up to 28 days
Secondary Proportion of patients using accessory muscles during NIV periods after 1 hour of NIV, up to 28 days
Secondary Daily arterial blood gases (ABG) (in terms of pH, PaCO2 and PaO2 measured between 8-10 am). up to 28 days post-randomisation
Secondary Proportion of patients with premature NIV cessation (intolerance) (defined by agitation and/or mask removal, and/or patient's wish to interrupt session before) 28 days post-randomisation
Secondary Proportion of patients refusing to resume NIV (despite meeting criteria) 28 days post-randomisation
Secondary Proportion of patients who need secondary intubation and IMV 28 days post-randomisation
Secondary Proportion of patients with nasal bridge ulceration After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days
Secondary Proportion of patients with eye irritation After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days
Secondary Proportion of patients with nasal congestion After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days
Secondary Proportion of patients with nasal/oral dryness After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days
Secondary Proportion of patients with gastric distension After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days
Secondary Proportion of patients with nosocomial pneumonia After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days
Secondary Proportion of patients with pneumothorax After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days
Secondary Proportion of patients with arterial hypotension After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days
Secondary Proportion of patients with nostril ulceration (including nasolabial angle, columella, nostril sill) After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days
Secondary Proportion of patients with nose bleeding After 2 hours of SB in the 48 first hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days
See also
  Status Clinical Trial Phase
Completed NCT02845076 - Weaning From Noninvasive Ventilation N/A
Recruiting NCT05008211 - Information-Motivation-Behavioral Skills Model-based Intervention to Domiciliary Non-invasive Ventilation of Patients N/A
Recruiting NCT03238339 - The Clinical Application and Popularization of Portable Home Noninvasive Ventilator
Recruiting NCT06047405 - NIV for Hypercapnic Respiratory Failure: AVAPS vs S/T BIPAP N/A
Completed NCT04108819 - Ketogenic Diet for Obesity Hypoventilation Syndrome N/A
Recruiting NCT02874339 - High Flow Nasal Oxygen Versus VNI in Acute Hypercapnic Cardiogenic Pulmonary Edema N/A
Not yet recruiting NCT05497986 - Conventional Low Flow Oxygenation Versus High Flow Nasal Cannula in Hypercapnic Respiratory Failure N/A
Completed NCT01987661 - The Effects of Airtrapping on Sleep and Breathing in Non Invasive Ventilation (NIV) in COPD N/A
Completed NCT03398239 - Comparison of BPAP ST/T and BPAP ST / T Mode With AVAPS for Hypercapnic Respiratory Failure in ED N/A
Terminated NCT03353064 - Telemedicine for Improving Outcome in Inner City Patient Population With Hypercapneic Respiratory Failure N/A
Completed NCT04072848 - Mathematically Arterialised Testing of Hypercapnic Subjects Study
Not yet recruiting NCT04131660 - Efficacy of Volume Ventilation in Patients With Acute Respiratory Failure at Risk of Obstructive Apneas or Obesity Hypoventilation N/A
Completed NCT02699112 - Cardiac and Respiratory Function With Non-invasive Ventilation
Completed NCT01523470 - Withdrawal of Non-invasive Ventilation in Chronic Obstructive Pulmonary Disease (COPD) Patients With Acute Hypercapnic Respiratory Failure Phase 3
Active, not recruiting NCT04709562 - Clinical Stabilization of Hypercapnia: NIPPV v HVNI N/A
Not yet recruiting NCT06064409 - Optimal Timing and Failure Prediction of High Flow Nasal Cannula Oxygen Therapy in Emergency Department: Prospective Observational Single Center Study
Recruiting NCT04351906 - Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome N/A
Not yet recruiting NCT06367686 - Detecting Systemic Carbon Dioxide Levels With a Novel Biosensor
Active, not recruiting NCT03364946 - High Flow Therapy in ICUs Across Ibero America
Not yet recruiting NCT06257667 - Treatment of Acute Hypercapnic Respiratory Failure With OptiflowTM or Optiflow+DuetTM Nasal Cannula in COPD-patients N/A